Patents by Inventor Eckhard Ottow

Eckhard Ottow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-methyl-homocysteines and their use as well as process for their production
    Patent number: 7659364
    Abstract: The synthesis of N-methyl-homocysteines and their use are described.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: February 9, 2010
    Assignee: CIS Bio International
    Inventors: Marc Willuhn, Johannes Platzek, Eckhard Ottow, Orlin Petrov, Claudia Borm, Dirk Hinz, Gregor Mann, John Lister-James, David M. Wilson
  • Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
    Patent number: 7479491
    Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: January 20, 2009
    Assignee: Novartis AG
    Inventors: Dieter Seidelmann, Martin Krueger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens
    Patent number: 7321044
    Abstract: The invention relates to intermediate products and a new process for the production of benzocycloheptene C. The process for the production of its new intermediate products according to the invention starts from economical starting materials, provides the intermediate stages in high yields and high purity, without chromatographic purification steps, and allows production on an industrial scale.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: January 22, 2008
    Assignee: Schering Aktiengesellschaft
    Inventors: Johannes Platzek, Wolfgang Beckmann, Jens Geisler, Holger Kirstein, Ulrich Niedballa, Eckhard Ottow, Sigmar Radau, Claudia Schulz, Thomas Wessa
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Patent number: 7297702
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11?,19-[4-(cyanophenyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11?,19-[4-(3-pyridinyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: November 20, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Krzysitof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Anthranilic acid amides and the use thereof as medicaments
    Patent number: 7122547
    Abstract: The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: October 17, 2006
    Assignees: Schering AG, Novartis AG
    Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Jürgen Mestan, Jose Brüggen, Stefano Ferrari, Martin Krüger, Eckhard Ottow, Andreas Menrad, Michael Schirner
  • Acyclic piperidine derivatives
    Patent number: 6949655
    Abstract: A compound having the formula (I): wherein: each R1, R2, R3 and R4 are independently selected from (C1-C10)-straight or branched alkyl, Ar-substituted- (C1-C10)-straight or branched alkyl, (C2-C10)-straight or branched alkenyl or alkynyl, or Ar-substituted-(C2-C10)-straight or branched alkenyl or alkynyl; wherein one to two CH2 groups of said alkyl, alkenyl, or alkynyl chains in each of R1, R2, R3 and R4 are optionally and independently replaced with O, S, S(O), S(O), S(O)2, C(O) or N(R5) in a chemically stable arrangement, wherein the CH2 group of R1 and R2 bound directly to said nitrogen cannot be replaced with C(O); or R1 and R2 taken together form a 4 to 7 membered ring; or R3 and R4 taken together form a 3 to 7 membered ring; wherein a CH2 in either the R1 and R2 ring system or the R3 and R4 ring system is independently and optionally replaced with O, C(O), N(R5), S, S(O), S(O)2 in a chemically stable arrangement; or wherein either or both of the R1 and R2 ring system and the R3 and R4 ring sy
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: September 27, 2005
    Inventors: David Lauffer, Ronald Tomlinson, Eckhard Ottow, Martyn Botfield
  • Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
    Publication number: 20050054692
    Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Application
    Filed: September 21, 2004
    Publication date: March 10, 2005
    Inventors: Dieter Seidelmann, Martin Kruger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Publication number: 20050026885
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11?,19-[4-(cyanophenyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11?,19-[4-(3-pyridinyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Application
    Filed: July 15, 2004
    Publication date: February 3, 2005
    Inventors: Krzysitof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors
    Patent number: 6818661
    Abstract: The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: November 16, 2004
    Assignee: Novartis AG
    Inventors: Dieter Seidelmann, Martin Krüger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Patent number: 6790853
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: September 14, 2004
    Assignee: Schering AG
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Publication number: 20030191102
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 9, 2003
    Applicant: Schering AG
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Acyclic piperazine and piperidine derivatives
    Publication number: 20030191117
    Abstract: The present invention relates to acyclic piperazine and piperidine derivatives, which are especially useful for treating or preventing neuronal damage, particularly damage associated with neurological diseases. These compounds are also useful for stimulating nerve growth. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage or for stimulating nerve growth.
    Type: Application
    Filed: June 13, 2002
    Publication date: October 9, 2003
    Inventors: David Lauffer, Ronald Tomlinson, Eckhard Ottow, Martyn Botfield
  • Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors
    Publication number: 20030176469
    Abstract: The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Application
    Filed: May 9, 2003
    Publication date: September 18, 2003
    Inventors: Dieter Seidelmann, Martin Kruger, Eckhard Ottow, Andreas Huth, Karl-heinz Thierauch, Andreas Menrad, Martin Haberey
  • Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens
    Publication number: 20030162974
    Abstract: The invention relates to intermediate products and a new process for the production of benzocycloheptene C.
    Type: Application
    Filed: October 15, 2002
    Publication date: August 28, 2003
    Applicant: Schering AG
    Inventors: Johannes Platzek, Wolfgang Beckmann, Jens Geisler, Holger Kirstein, Ulrich Niedballa, Eckhard Ottow, Sigmar Radau, Claudia Schulz, Thomas Wessa
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Patent number: 6608074
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: August 19, 2003
    Assignee: Schering AG
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Steroid esters and amides, process for their production and their pharmaceutical use
    Patent number: 6596713
    Abstract: New steroids and amides of formula I are described, in which the variables are defined by the description. Relative to the basic hydroxy compounds (“initial compounds”), the new compounds are distinguished by a considerably improved solubility and partially also by increased biological action and selectivity. The new compounds are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: July 22, 2003
    Assignee: Schering Aktiengesellschaft
    Inventors: Ulrich Klar, Arwed Cleve, Guenter Neef, Eckhard Ottow, Klaus Stoekemann, Karl-Heinrich Fritzemeier
  • N-methyl-homocysteines and their use as well as process for their production
    Publication number: 20030120032
    Abstract: The synthesis of N-methyl-homocysteines and their use are described.
    Type: Application
    Filed: November 15, 2002
    Publication date: June 26, 2003
    Applicant: Schering AG
    Inventors: Marc Willuhn, Johannes Platzek, Eckhard Ottow, Orlin Petrov, Claudia Borm, Dirk Hinz, Gregor Mann, John Lister-James, David M. Wilson
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Publication number: 20020058649
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Application
    Filed: November 28, 2001
    Publication date: May 16, 2002
    Applicant: Schering AG
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Patent number: 6340688
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: January 22, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Heteroaromatic compounds
    Patent number: 6284779
    Abstract: The invention relates to the compounds of Formula I as well as the process for their production and their use as pharmaceutical agents.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: September 4, 2001
    Assignees: Schering Aktiiengesellschaft, Vertex Pharmaceuticals Incorporated
    Inventors: Thomas Brumby, Fiona McDonald, Eckhard Ottow, Herbert Schneider